Bright Minds Biosciences Inc
CNSX:DRUG
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
1.3
102.72
|
Price Target |
|
We'll email you a reminder when the closing price reaches CAD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one DRUG stock under the Base Case scenario is 4.43 CAD. Compared to the current market price of 56.3 CAD, Bright Minds Biosciences Inc is Overvalued by 92%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Bright Minds Biosciences Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for DRUG cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Bright Minds Biosciences Inc
Balance Sheet Decomposition
Bright Minds Biosciences Inc
Current Assets | 6.3m |
Cash & Short-Term Investments | 6.2m |
Receivables | 17.2k |
Other Current Assets | 58.3k |
Non-Current Assets | 12.1k |
PP&E | 12.1k |
Other Non-Current Assets | -10 |
Current Liabilities | 178.6k |
Accounts Payable | 149.6k |
Accrued Liabilities | 15k |
Other Current Liabilities | 14k |
Earnings Waterfall
Bright Minds Biosciences Inc
Revenue
|
0
CAD
|
Operating Expenses
|
-3.6m
CAD
|
Operating Income
|
-3.6m
CAD
|
Other Expenses
|
41.6k
CAD
|
Net Income
|
-3.6m
CAD
|
Free Cash Flow Analysis
Bright Minds Biosciences Inc
CAD | |
Free Cash Flow | CAD |
DRUG Profitability Score
Profitability Due Diligence
Bright Minds Biosciences Inc's profitability score is 45/100. The higher the profitability score, the more profitable the company is.
Score
Bright Minds Biosciences Inc's profitability score is 45/100. The higher the profitability score, the more profitable the company is.
DRUG Solvency Score
Solvency Due Diligence
Bright Minds Biosciences Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Bright Minds Biosciences Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
DRUG Price Targets Summary
Bright Minds Biosciences Inc
Dividends
Current shareholder yield for DRUG is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Bright Minds Biosciences, Inc. is a biotechnology company, which engages in developing therapeutics to improve the lives of patients with severe and life-altering diseases. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2021-02-08. The firm is focused on developing transformative treatments for neuropsychiatric disorders, epilepsy and pain. The firm has a portfolio of serotonin agonists designed to target neurocircuit abnormalities to treat disorders, such as resistant epilepsy, treatment resistant depression, post-traumatic stress disorder (PTSD), and pain. The company is focused on developing a line of serotonergic 5-Hydroxytryptamine (5-HT) drug candidates that target the 5-HT2C, 5-HT2A and 5-HT2A + 5-HT2C receptors. Its offers 5-HT2C for the treatment of dravet syndrome and behavioral disorders. Its offers 5-HT2A for treatment of depression and other neuropsychiatric disorders. Its offers 5-HT2A + 5-HT2C for several chronic pain disorders/neuropathic pain syndromes, including cluster headaches and chemotherapy-induced peripheral neuropathy.
Contact
IPO
Employees
Officers
The intrinsic value of one DRUG stock under the Base Case scenario is 4.43 CAD.
Compared to the current market price of 56.3 CAD, Bright Minds Biosciences Inc is Overvalued by 92%.